Small-molecule Complement Inhibitors
Small-Molecule Complement Inhibitor is a pharmacological agent that belongs to the class of complement-targeted therapies and is distinguished by its low molecular weight, enabling oral bioavailability and specific modulation of complement system proteins to inhibit pathological immune activation.
92
Publications
5.3K
Citations
743
Authors
255
Institutions
Publications per year
2017–2026
27
92
Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection
Marceline Côté, John Misasi, Tao Ren et al. · Nature · 2011 · 694 citations · Full text
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Richard J. Kelly, Britta Höchsmann, Jeff Szer et al. · New England Journal of Medicine · 2015 · 275 citations · Full text
1–5 of 92
743
8
h-index
7
h-index
6
h-index
6
h-index
5
h-index
1–5 of 743
255
Novartis (Switzerland)
Basel, Switzerland
10 h-index
102 publications
8.9K citations
University of Pennsylvania
Philadelphia, United States
8 h-index
26 publications
2.3K citations

University of Mississippi
Oxford, United States
6 h-index
17 publications
433 citations
Novartis (United States)
New York, United States
6 h-index
84 publications
3.3K citations
Cardiff University
Cardiff, United Kingdom
5 h-index
11 publications
837 citations

Washington University in St. Louis
St Louis, United States
5 h-index
14 publications
962 citations
Novartis Institutes for BioMedical Research
Basel, Switzerland
5 h-index
31 publications
1.2K citations

University of Naples Federico II
Naples, Italy
4 h-index
9 publications
1.5K citations
1–8 of 255
10 publications · 570 citations
10
h-index
9 publications · 183 citations
9
h-index
7 publications · 558 citations
7
h-index
6 publications · 139 citations
6
h-index
JI · 5 publications · 153 citations
5
h-index
1–5